Press Releases

07.01.2016

BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.

06.28.2016

Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results

06.27.2016

Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

06.24.2016

Pfizer Completes Acquisition of Anacor

06.21.2016

Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts

06.16.2016

Help Pfizer Change The Future Of Healthy Aging

06.16.2016

Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts

06.14.2016

Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio

06.12.2016

Pfizer Announces Final Results from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

06.11.2016

Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes

06.09.2016

Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination

06.08.2016

Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval